Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.
about
Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cellsHistidine triad nucleotide-binding protein 1 (HINT-1) phosphoramidase transforms nucleoside 5'-O-phosphorothioates to nucleoside 5'-O-phosphatesRenal autoregulation in health and diseaseEliciting the low-activity aldehyde dehydrogenase Asian phenotype by an antisense mechanism results in an aversion to ethanolAntisense knockdown of inducible nitric oxide synthase inhibits the relaxant effect of VIP in isolated smooth muscle cells of the mouse gastric fundusAnti-human immunodeficiency virus type 1 activity of phosphorothioate analogs of oligodeoxynucleotides: penetration and localization of oligodeoxynucleotides in HIV-1-infected MOLT-4 cellsAntisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cellsSelf-stabilized antisense oligodeoxynucleotide phosphorothioates: properties and anti-HIV activityLong-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioatesSequence-specific inhibition of gene expression by a novel antisense oligodeoxynucleotide phosphorothioate directed against a nonregulatory region of the human immunodeficiency virus type 1 genome.Cytosolic malate dehydrogenase confers selectivity of the nucleic acid-conducting channelIntracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity.Involvement of dopamine D2 receptor in the diurnal changes of tuberoinfundibular dopaminergic neuron activity and prolactin secretion in female ratsCorrelation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1.Non-clinical safety studies of IMT504, a unique non-CpG oligonucleotide.Determination of therapeutic oligonucleotides using capillary gel electrophoresis.Potential roles of antisense technology in cancer chemotherapy.Gene silencing by gold nanoshell-mediated delivery and laser-triggered release of antisense oligonucleotide and siRNA'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents.CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infectionOligonucleotides with conjugated dihydropyrroloindole tripeptides: base composition and backbone effects on hybridization.Quantitative PCR analysis of DNA aptamer pharmacokinetics in mice.In vivo stability and kinetics of absorption and disposition of 3' phosphopropyl amine oligonucleotidesTargeted inhibition of gene expression of pancreatitis-associated proteins exacerbates the severity of acute pancreatitis in rats.The p75 nerve growth factor receptor mediates survival or death depending on the stage of sensory neuron development.Clearance kinetics, biodistribution, and organ saturability of phosphorothioate oligodeoxynucleotides in miceAntisense oligonucleotide inhibition of heat shock protein (HSP) 47 improves bleomycin-induced pulmonary fibrosis in rats.Identification and characterization of a cell membrane nucleic acid channel.Encapsulation of oligonucleotides in stealth Me.PEG-PLA50 nanoparticles by complexation with structured oligopeptides.Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotidesAntisense oligonucleotides in the treatment of bladder cancer.Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studiesCholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic MiceEffect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo.Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future NeedsStability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system.Inhibition of Rev activity and human immunodeficiency virus type 1 replication by antisense oligodeoxynucleotide phosphorothioate analogs directed against the Rev-responsive element.Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration.Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A.Systemic delivery of triplex-forming PNA and donor DNA by nanoparticles mediates site-specific genome editing of human hematopoietic cells in vivo.
P2860
Q24313109-E04193AC-1E4B-45A4-BE7B-72E2F0FFEB0EQ27664985-B2A9C847-0381-4623-86EC-118D0A591B2DQ28082365-E70A375C-6D2A-45D3-B330-2C26595BF203Q28349277-D1A869CC-76A3-40F1-883D-00D746470A54Q28359458-5981F133-E943-4F01-B8F9-AE4493DF16E6Q28367621-E74D2DCC-89A9-44CD-BAF6-B93FCBD6ABBAQ28369354-E2EF55C7-348F-4A2C-B8D0-14D1ED732145Q28378628-FDB53DD1-4755-4C30-BBBC-9F8860A3985EQ28378692-7A84C1C8-F365-4933-A989-4DA7CC5DC300Q30452649-C084717B-9412-4A71-ABF0-0B16C64E0C6CQ30453758-219F8E96-5D9A-4D60-905A-2BCEBF5AF351Q31009736-775E32AB-3C60-4C7D-B277-5F1349E819F5Q33603752-AB5037B2-79DA-43F3-9AB7-A3996F77F709Q33657678-A449A33F-CC41-4E55-9592-1CA2D232ACDFQ33931430-25A392E5-8185-44B8-90BE-9C7E3E67FD87Q34013085-62E995EE-6BF0-43EC-BB82-09E152C8281AQ34293601-804B33F0-26A9-4933-BB62-CF06BF845023Q34365466-BF39CAEA-D9EC-421F-BDC9-4B744ECD2149Q34368468-EB70CB57-2839-4966-B29C-EF2C90791AD4Q34402230-DB8F63CC-4A58-42F0-BD08-1CAA2EC55C83Q34636286-11EDBF9F-F833-437B-8EE7-43D2CFE2C3B6Q34976853-AA4FEBB6-C56E-46F9-B40F-268E07E63DB8Q35012323-7C80FE3F-AC45-430E-BB7C-D629180E34B0Q35152043-4EBC110F-8473-4404-8CC2-C3C0C415D7A0Q35578716-EF35A884-9F0A-40A0-993A-8695BBEC5A01Q35782543-93C40289-C56E-4609-AA95-2489360E726FQ35808541-3272BC8F-7F81-49BB-93EE-96EB4018A470Q35896079-6410AE9C-3772-4E15-9A23-38F7C910B599Q35899304-FCC0FE4F-6BED-47D0-99D4-19BCEA98EE10Q35935577-048E0D7E-56C0-4191-9288-8D96ED819657Q36040819-2957C5C9-7AD1-4478-98D8-F3B1BE9C13B9Q36052460-E15BE578-6482-40B0-AC72-A88BD970423CQ36086300-5A5FF7A0-9411-4D30-B8CD-EC5ECB03C2DBQ36135764-80A713DD-CD33-4C12-B613-C864F8447E31Q36191001-D7024FEC-701D-4FE0-8DD0-D557D951F96EQ36310853-9760504B-5D29-4818-96A8-B91ED5403A87Q36654713-A06069CD-E613-41AC-A7B7-1557BE36F81FQ36705221-19EBC273-BB2A-42B7-9109-992A0F70DE93Q36824952-8E711BE6-0967-42C0-8D5D-4E3EFD6E6807Q37019421-169D8D91-3B5B-46A9-8056-C0C9C8F955DD
P2860
Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 1991
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacokinetics, biodistribut ...... ide phosphorothioates in mice.
@en
Pharmacokinetics, biodistribut ...... ide phosphorothioates in mice.
@nl
type
label
Pharmacokinetics, biodistribut ...... ide phosphorothioates in mice.
@en
Pharmacokinetics, biodistribut ...... ide phosphorothioates in mice.
@nl
prefLabel
Pharmacokinetics, biodistribut ...... ide phosphorothioates in mice.
@en
Pharmacokinetics, biodistribut ...... ide phosphorothioates in mice.
@nl
P2093
P2860
P356
P1476
Pharmacokinetics, biodistribut ...... ide phosphorothioates in mice.
@en
P2093
P2860
P304
P356
10.1073/PNAS.88.17.7595
P407
P577
1991-09-01T00:00:00Z